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Abstract
Background: Tedizolid, the active moiety of tedizolid phosphate, is approved in the United States, the European
Union, Canada and a number of other countries for the treatment of acute bacterial skin and skin structure
infections (ABSSSI) caused by certain susceptible bacteria, including methicillin-resistant Staphylococcus aureus
(MRSA). This network meta-analysis (NMA) evaluates the comparative effectiveness of tedizolid and other
antibacterials indicated for the treatment of ABSSSI caused by MRSA.
Methods: Systematic review of 10 databases was undertaken to inform an NMA to estimate the relative
effectiveness of tedizolid and established monotherapy comparators (ceftaroline, daptomycin, linezolid, teicoplanin,
tigecycline, vancomycin) for treating MRSA-associated ABSSSI. Randomized controlled trials enrolling adults with
ABSSSI or complicated skin and skin structure infections caused by suspected/documented MRSA were eligible for
inclusion. Networks were developed based on similarity of study design, patient characteristics, outcome measures
and available data. Outcomes of interest included clinical response at end of therapy (EOT), post-therapy evaluation
(PTE) or test-of-cure assessment and treatment discontinuations resulting from adverse events (AEs). Bayesian NMA
was conducted for each outcome using fixed-effects and random effects models.
Results: Literature searches identified 3,618 records; 15 trials met the inclusion criteria and were considered suitable
for NMA comparison. In fixed-effects models, tedizolid had higher odds of clinical response at EOT (odds ratio [OR],
1.7; credible interval, 1.0, 3.0) and PTE than vancomycin (OR, 1.6; credible interval, 1.1, 2.5). No differences in odds of
clinical response at EOT or PTE were observed between tedizolid and other comparators. There was no evidence of
a difference among treatments for discontinuation due to AEs. Results from random effects and fixed-effects
models were generally consistent.
Conclusions: Tedizolid was superior to vancomycin for clinical response at EOT and PTE. There was no evidence of
a difference between tedizolid and other comparators and no evidence of a difference between tedizolid and all
comparators when evaluating discontinuation due to AEs. These findings suggest that tedizolid provides an
alternative option for the management of serious skin infections caused by suspected or documented MRSA.
This study is subject to the limitations inherent in all NMAs, and the results should be interpreted accordingly.
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Background
Acute bacterial skin and skin structure infection (ABSSSI)
is a relatively new classification of skin infections intro-
duced by the US Food and Drug Administration (FDA) in
2010 [1]. ABSSSI is defined as ‘a bacterial infection of the
skin with a lesion size area of at least 75 cm2 (lesion size
measured by the area of redness, edema, or induration)’
and includes the following infection types: cellulitis/erysip-
elas, wound infection and major cutaneous abscess [1].
These infections are also encompassed by the definitions
of ‘complicated skin and soft tissue infections’ (cSSTI) or
‘complicated skin and skin structure infections’ (cSSSI),
but cSSTI/cSSSI classifications also extend to other types
of skin infections, such as diabetic foot ulcers.
cSSTI and ABSSSI are among the most rapidly increasing
reasons for hospitalization in the United States [2]. Com-
mon bacterial pathogens causing ABSSSI are Staphylococcus
aureus, including methicillin-resistant S. aureus (MRSA),
and Streptococcus pyogenes [1, 3]. MRSA is a significant
cause of both health care–associated and community-
associated skin and soft tissue infections [4]. It is associated
with worse outcomes and higher costs of care than other
pathogens, such as methicillin-susceptible S. aureus (MSSA),
not only for skin and soft tissue infections but also for
pneumonia, bacteraemia and diabetic foot infections [5].
Practice guidelines for the diagnosis and management of
skin and soft tissue infections published in 2005 suggest
that in specific cases of S. aureus infection, clinicians
should assume that the organism is methicillin resistant
because of the high prevalence of community-associated
MRSA strains and, therefore, use agents effective against
MRSA [6]. Updated guidelines, published in 2014, place
an emphasis on the importance of establishing the cause
of the infection and considering pathogen-specific and
local resistance patterns due to the emergence of resist-
ance to many commonly used treatment agents [7].
Standard therapy for MRSA infections has historically
been vancomycin. However, the efficacy of vancomycin
has increasingly been called into question, with concerns
over its slow bactericidal activity and the emergence of less
susceptible and resistant strains [5]. At the time of this
study (February 2014), alternative available treatments for
MRSA included teicoplanin, tigecycline, ceftaroline, dapto-
mycin, telavancin and linezolid [3, 5, 8]; in the meantime,
oritavancin and dalbavancin also entered the marketplace.
Tedizolid phosphate is a novel, potent oxazolidinone
prodrug that is rapidly converted to microbiologically active
tedizolid. Tedizolid binds to the bacterial 50S ribosomal
subunit to inhibit protein synthesis, resulting in broad
in vitro activity against Gram-positive pathogens, including
MRSA and selected strains resistant to vancomycin or
linezolid [9, 10]. Tedizolid is approved in a number of
countries, including the United States, Canada and those of
the European Union, for the treatment of ABSSSI caused
by certain susceptible bacteria including MRSA [1]. Two
phase 3 randomized controlled trials (RCTs) have been con-
ducted that compared tedizolid with linezolid, but, at the
time of our study, there were no other head-to-head com-
parisons of tedizolid with any other relevant comparators.
In light of the limited amount of head-to-head data and
to explore the comparative effectiveness of tedizolid, we
conducted a systematic review and network meta-analysis
(NMA) to compare the effectiveness of tedizolid with other,
established therapies for treating serious skin infections
caused by MRSA.
Methods
The systematic review was conducted according to the prin-
ciples of systematic reviewing as set out in guidance from
the Centre for Reviews and Dissemination [11] and the Na-
tional Institute for Health and Care Excellence (NICE) [12].
Relevant trials were identified and selected according to a
systematic review protocol (Additional file 1: Appendices)
and process, and reporting conformed to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [13]. This protocol has not been
registered.
Eligibility criteria
Eligible studies were RCTs of any size and duration,
published in English, that evaluated tedizolid, vancomycin,
linezolid, daptomycin, teicoplanin, tigecycline, ceftaroline
or telavancin for the treatment of MRSA-associated
ABSSSI in adults with suspected or documented MRSA-
ABSSSI or cSSSI.
Studies that compared any of the above treatments of
interest as monotherapy were eligible for inclusion in the
NMA, but studies assessing combinations of treatments
were not eligible. Included studies could be of any treat-
ment duration and any length of follow-up. Outcomes of
interest to this review were clinical response rate at early
assessment (48–72 h) and at test of cure (TOC) or similar
endpoint, rates of nephrotoxicity and serious adverse
events (AEs) leading to treatment discontinuation. Full
details of study eligibility and the outcomes assessed can
be found in the online Additional file 1: Appendix A.
Exclusion criteria are presented in Appendix C.
Study identification and selection
The search strategy was structured to search for two
concepts: (ABSSSI or cSSSI) AND (named comparators)
AND RCTs. The RCT filter was based on the Cochrane
Highly Sensitive Search Strategy for identifying randomized
trials in MEDLINE: sensitivity-maximizing version (2008
revision), Ovid format [14].
Searches were conducted in February 2014 in a range of
relevant databases of published research, as recommended
by systematic review guidelines. The search focused on
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identifying fully published reports; searches for conference
abstracts were not conducted. Ten databases were
searched: MEDLINE In-Process & Other Non-Indexed
Citations and MEDLINE (via OvidSP), EMBASE (via
OvidSP), Science Citation Index Expanded (via Web of
Science), Cochrane Database of Systematic Reviews (via
Cochrane Library/Wiley), Cochrane Central Register of
Controlled Trials (via Cochrane Library/Wiley), Database of
Abstracts of Reviews of Effects (via Cochrane Library/Wi-
ley), Health Technology Assessment Database (via Cochrane
Library/Wiley), ClinicalTrials.gov (via http://www.clinical-
trials.gov), International Clinical Trials Registry Platform (via
http://apps.who.int/trialsearch/) and metaRegister of Con-
trolled Trials (via http://www.controlled-trials.com/mrct/).
The searches were not limited by date range or language.
Details of the search strategy for MEDLINE are reported in
the online Additional file 1: Appendix B; this strategy was
translated appropriately for other databases.
Records were assessed by one reviewer for relevance on
the basis of information provided in the title and abstract,
and a sample of records was checked by a second
reviewer; any disagreements were discussed with a third
reviewer. Full-text copies of potentially relevant docu-
ments were obtained and evaluated against the eligibility
criteria defined in the protocol (Appendix A). The full-text
assessment was undertaken by two independent
reviewers, with a third reviewer to adjudicate any
disagreements. Studies that were excluded following
full-text assessment are reported in the online Additional
file 1: Appendix C, along with the reason for exclusion.
Determining the suitability of indirect comparisons
Following the identification of relevant studies, theoretical
networks were produced based on the interventions and
comparators in each trial. Network diagrams showing
which of the treatments and comparator treatments were
linked for each outcome were developed; any assumptions
made to connect the networks were clearly described, and
the implications of the assumptions were discussed.
To assess the similarity of studies, we adapted the guid-
ance produced by the Australian Pharmaceutical Benefits
Advisory Committee (PBAC) [15] on best practice for the
conduct of indirect and mixed-treatment comparisons. The
PBAC guidance suggests that the similarity of the studies in
each network should be assessed by evaluating the following
elements: quality of methods used in conducting random-
ized trials, confounding factors in relation to participant
populations, confounding factors in relation to circum-
stances, similarity of treatments (common reference and
interventions) and similarity of outcomes and measures.
Data extraction
Data extraction of each of the included studies in the
systematic review was carried out by two independent
reviewers using a standardized data extraction form to
capture these similarity elements in DistillerSR software. A
third reviewer compared the extractions and highlighted
any disagreements for discussion.
Key study characteristics, populations, treatments and
efficacy and safety outcomes data were used to determine
whether studies were sufficiently similar to combine in an
NMA and to assess which studies provided usable data for
the outcomes of interest. The following outcomes were
selected as priorities for the NMA: clinical response at
early assessment (48-72 h after the first dose of study
medication and investigator assessed), end of therapy
(EOT) evaluation, post-therapy evaluation (PTE) or TOC,
AEs leading to discontinuation and nephrotoxicity.
Network meta-analysis
Networks were developed based on similarity in study design,
outcome measures and available data. NMA methods were
informed by the good research practice guidelines developed
by the International Society for Pharmacoeconomics and
Outcomes Research task force [16] and PBAC [15].
Differences between treatments within studies were
analyzed in the context of a network of treatment compari-
sons. For each outcome, the NMA synthesized the results
across the studies to give overall estimates of the odds
ratios for each pair of treatments within the network.
Standard Bayesian methodology for NMA was applied to
all outcomes. All analyses were conducted using WinBUGS
version 1.4.3 [17] and R version 3.1.1 [18]. The package
‘R2WinBUGS’ was used to run WinBUGS from within R
[19]. The WinBUGS code for the models is provided in the
online Additional file 1: Appendix D.
Both fixed-effects and random effects models were fitted
to the data. Due to the moderate to limited information
available to estimate the between-study variance, only
results for the fixed-effects models are discussed in the
main body of the paper.
Statistical heterogeneity was assessed for each outcome,
for each pairwise treatment comparison informed by at
least two trials. Heterogeneity was measured by the I2
statistic, where I2 values of 25%, 50% and 75% were
considered to indicate low, moderate and high
heterogeneity, respectively [20]. Inconsistency—the lack of
agreement between direct and indirect evidence in an
NMA—was also assessed for each loop in the networks.
Inconsistency was assessed by the Bucher method, as
described in the NICE Decision Support Unit Technical
Support Document [21].
Results
Literature review and network development
Included studies
Fifteen trials (16 reports) met the inclusion criteria for
the systematic review and NMA. A flow diagram of the
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numbers of studies included and excluded at each stage
of the selection process is provided in Fig. 1.
Feasibility assessment
Following identification of relevant studies, the similarity
of the trials was assessed to determine whether it would
be appropriate to combine the trials in an NMA. All 15
trials evaluated in the feasibility assessment were included
in the NMA.
Determining the similarity of studies for indirect
comparisons
The interventions assessed in the 15 eligible trials are
summarized in Table 1. A summary of the similarity of
trials for each criterion in the PBAC tool, highlighting any
key differences, is presented in the following sections, and
the detailed assessment is presented in the online
Additional file 1: Appendix E.
Trial design and quality
All included trials were reported to be RCTs. However, the
type and degree of blinding or allocation concealment was
variable across trials, representing a potential source of
heterogeneity. Seven trials were open label [22–28], three
were single blind [29–31] (two in which the assessors were
blinded [30, 31]), four were double blind [9, 10, 32, 33] and
one did not report details of blinding [34].
The exact outcome assessed for each trial may be a fur-
ther source of heterogeneity because the precise definition
of clinical response varied from study to study.
Across the trials, similar treatment time periods were
assessed and the follow-up time was generally similar for
the EOT and end-of-study time points. With one exception
[34], the proportion of patients lost to follow-up or missing
data was similar across treatment arms within a trial, and
these proportions were generally similar across trials (with
the exception of Wilcox et al 2004 and Stryjewski et al,
2007 [28, 33]). Large proportions and/or different propor-
tions lost to follow-up between treatment arms can be a
source of attrition bias.
Analysis population
There was variation in the population groups analyzed,
and several trials reported data for a number of popula-
tions. A number of trials assessed the intention-to-treat
(ITT) population, but most trials assessed a modified ITT
(mITT) population comprising only patients who received
a baseline amount of a drug and/or patients who were
evaluable (definitions varied across trials) or those who
followed the protocol (to varying degrees). Most studies
were conducted in the United States (n = 11); 3 studies
Fig. 1 PRISMA flow diagram [13] for the review and NMA
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were conducted in Asia and 2 in Europe. The various pop-
ulations defined in the trials and for whom data are
reported are presented in the online Additional file 1:
Appendix E, section E.4.
Participant populations
Across the 15 trials and between treatment arms, popula-
tions were broadly similar in terms of eligible age, actual age
and sex. Diagnostic workup was generally well reported by
the trials, but there were some differences in the criteria
used to determine infection and/or MRSA infection likely
due to the variability of presentation of infection symptoms.
Variability existed between the trials in the proportions
of patients with cellulitis, wounds, abscess and other types
of infection, each varying from approximately 10% to 50%.
In general, variability existed between trials rather than
between treatment arms within the same trial. Some
studies, particularly those that included patients with non-
SSSI infections, did not report details of infections, and
type of infection was not taken into consideration in the
NMA. Trials also varied in the proportion of patients with
confirmed MRSA. This variability reflected the differing
scopes of the trials, some of which focused on MRSA [32]
whereas others focused on a wider scope of infective
pathogens [31]. With the exception of the variability in
the infection details between studies, the baseline popula-
tion characteristics of the included trials did not present
major heterogeneity for this proposed NMA.
Common treatment arms
Similarity assessments of the treatment arms common to
more than one study, and that feature in the NMA, were
also undertaken. For most treatments, the treatment dose,
schedule and duration were similar across trials and did not
present heterogeneity issues for the potential NMA. The ex-
ception was vancomycin, for which the treatment duration
was 7 to 14 days in seven studies and up to 21 or 28 days in
the other four studies, three of which included patients with
a range of infections (i.e. not restricted to skin infections),
which could explain the longer treatment durations [24, 32,
34]. There were also some differences in the administration
methods for tedizolid and linezolid because both treatments
could be administered orally or intravenously.
Conclusions of the feasibility assessment
The primary network analyzed included all trials with data
for the particular outcome (network designated as ‘all trials’).
However, the difference in the analysis populations across
the trials was considered a notable source of heterogeneity.
Therefore, these differences were explored further in a sensi-
tivity analysis. Where data were reported for multiple popu-
lations in one trial, data for the ITT population, or those of
the population that most closely resembled the ITT popula-
tion, were used. A second network was then analyzed that
included only the trials reporting data for an ITT or a modi-
fied population (network identified as ‘ITT/mITT’).
The primary population of interest to this review was
patients with MRSA-associated ABSSSI. Several of the
trials, however, included patients with infections caused
by other Gram-positive pathogens. For this reason, a third
network was also explored for each outcome that included
only trials of patients with confirmed MRSA or trials
reporting data for subgroups of patients with confirmed
MRSA (network identified as ‘MRSA only’).
Overall, though there were some differences in the study
methods and patient populations included in the identified
trials, the studies were deemed similar enough for reasonable
estimates to be derived of the comparative efficacy of the
treatments using methods of indirect treatment comparison.
Network meta-analysis
Fifteen studies contributed to the NMA. The full network
diagram with all the included trials is presented in Fig. 2.
The outcomes of clinical response at EOT and PTE/TOC
and AEs leading to discontinuation had connected net-
works and were selected for analysis in the NMA. It was
not possible to create a connected network comparing tedi-
zolid and the comparators of interest for clinical response
at early assessment or nephrotoxicity. The networks varied
depending on the data available in each trial; none of the
NMA included all 15 trials. In total, 14 studies contributed
to the all-trials network, 12 studies to the ITT/mITT net-
work and eight studies to the MRSA-only network. Table 1
identifies the treatments included in each study and illus-
trates which studies are included in each network.
Assessment of heterogeneity and inconsistency
No significant heterogeneity was found between any of
the pairwise comparisons for clinical response at EOT and
discontinuations due to AEs. For clinical response at PTE,
the linezolid versus vancomycin comparison showed mod-
erate to high heterogeneity between the trials.
Inconsistency could be checked only for clinical re-
sponse at PTE because this was the only network with a
closed loop (between the vancomycin, telavancin and
daptomycin treatments). No inconsistency was found.
Table 2 shows the results for tedizolid and each of the
seven comparator treatments; credible intervals (CrI) that
did not cross 1 and favoured tedizolid are in bold text.
Clinical response at end of treatment
Results for two networks, corresponding to two different
populations, were estimated: all trials and ITT/mITT
(Table 2, Fig. 3). The NMA results for all trials suggested
that tedizolid was superior to vancomycin (odds ratio
[OR], 1.7; CrI, 1.0, 3.0). There was no evidence of a differ-
ence between tedizolid and any of the other comparators
assessed for the all-trials and ITT/mITT networks.
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Similar results were found for the random effects models.
Based on all trials, the tedizolid versus vancomycin estimate
was similar, but the CrI was wider and included 1 (online
Additional file 1: Appendix F). Limited information was
available to estimate the between-study variance for the
random effects model, which contributes to the wider CrI
estimated.
Clinical response at the post-treatment evaluation or test of cure
Results for three networks, corresponding to different pop-
ulations, were estimated: all trials, ITT/mITT and MRSA
only (Table 2, Fig. 4). Results of the fixed-effects model in
both the all-trials and the ITT/mITT networks suggest that
the odds of a clinical response at PTE or TOC were higher
for tedizolid than for vancomycin (OR, 1.6; CrI, 1.1, 2.5;
Fig. 2 Network diagram of studies of ABSSSI treatment
Table 2 Fixed-effects results of NMA comparing tedizolid with each of the seven comparator drugs (odds ratios [95% credible intervals])
Outcome Comparator Drug
Ceftaroline Daptomycin Linezolid Teicoplanin Telavancin Tigecycline Vancomycin










































































Bold text indicates CrI that do not cross 1 and favour tedizolid
AE adverse event, CRI credible intervals, EOT end of treatment, ITT intention to treat, mITT modified intention to treat, MRSA methicillin-resistant Staphylococcus
aureus, NA not available, PTE post-treatment evaluation, TOC test of cure
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Fig. 4). Linezolid was also found to be superior to vanco-
mycin and telavancin in these networks. For the MRSA-
only network, linezolid was found to be superior to vanco-
mycin. However, given that significant heterogeneity was
found for the linezolid versus vancomycin comparison for
all three networks, conclusions should be drawn with care.
There was no evidence of a difference between any of the
other comparisons assessed.
Post hoc sensitivity analysis
After the analysis was completed, it became clear that the
exclusion of combination therapies led to exclusion of a
known publication for which pathogen-specific results
were available. A post hoc analysis was conducted to
facilitate a comparison with ceftaroline and included a
study that evaluated ceftaroline monotherapy compared
with a combination treatment arm (vancomycin with and
without aztreonam) [35]. This post hoc analysis was con-
ducted for the clinical response at PTE/TOC and for the
MRSA-only population. The results were similar to those
obtained for the main analysis. There was no evidence of a
difference between tedizolid and the other treatments.
Discontinuation due to adverse events
There was no evidence of a difference between any of the
treatments for discontinuation due to AEs: all comparisons
had CrI that included 1 (Table 2, Fig. 5).
Discussion
This systematic review and NMA evaluated the compara-
tive effectiveness of tedizolid and other, established antibac-
terial agents indicated for treatment of ABSSSI caused by
Fig. 3 Clinical response at the end of treatment: all trials. Odds ratios (fixed-effects model)
Fig. 4 Clinical response at the post-treatment evaluation or test of cure: all trials. Odds ratios (fixed-effects model)
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MRSA. Given the expense and difficulties of conducting
further RCTs to directly compare the increasing variety of
agents available for treating serious MRSA infections, it is
opportune that we now have robust methods through
NMA for comparing the relative efficacy of new and estab-
lished agents by indirect means. A previous NMA of anti-
bacterials used to treat MRSA infection was published
before tedizolid was approved [36]; however, the challenges
associated with treating ABSSSI in the era of resistant bac-
teria mean that up-to-date evaluations of new treatments
are critical to inform treatment decisions. In the current
analysis, tedizolid was superior to vancomycin for clinical
response at EOT (all-trials data); there was no evidence of a
difference between tedizolid and linezolid, ceftaroline or
teicoplanin. For clinical response at PTE, tedizolid was
superior to vancomycin, and there was no evidence of a
difference compared with linezolid, daptomycin, tigecycline,
ceftaroline and telavancin. The lack of a difference between
the latter antibacterials is consistent with findings previ-
ously reported by Bally et al [36], which resulted from an
NMA conducted in the same setting before tedizolid data
were available. That analysis also suggested that some
antibacterial agents, including the oxazolidinone linezolid
(to which tedizolid was shown to be non-inferior in terms
of efficacy), were more effective and safer than vancomycin
for treating hospital patients with cSSTI caused by MRSA.
Tedizolid was found to be equivalent to all comparators
when evaluating discontinuation due to AEs.
This study is subject to the limitations inherent to all
NMAs in terms of the quality of included studies, publica-
tion bias and limited data [37], and the results should be
interpreted accordingly. Flaws in the design, conduct and
analysis of RCTs can lead to bias and raise questions about
the validity of the studies’ findings. In this review, a simi-
larity assessment of studies eligible for inclusion in the
networks was undertaken, as was a detailed assessment of
the risk of bias for each trial identified. The included trials
varied in design and quality: some were double-blind but
others were not blinded, and, in general, limited informa-
tion was reported on methods of randomization, sequence
generation and sequence allocation. Results of the NMA
should be considered in light of these uncertainties
around bias. The trials also differed in terms of definitions
of clinical response, and information regarding how AEs
were defined was limited. It was assumed that these
factors would be similar for the purpose of these analyses.
Most trials did not explicitly report methods used to
account for missing data, so the impact of different
methods cannot be assessed.
Several other limitations of this NMA should be noted
when evaluating the results. Some studies, particularly
those that included non-SSSI infections, did not report
details of the infection site. Furthermore, the trials dif-
fered in the relative proportions of skin infection type
(i.e. cellulitis, wounds, abscesses, other infections). In
addition, the analysis included trials assessing outcomes
in ABSSSI and cSSSI despite their different definitions,
treatment approaches and treatment outcomes.
The trials also varied in the proportion of patients with
confirmed MRSA. This variability reflects the differing
scopes of the trials, some of which focused exclusively
on suspected or confirmed MRSA, whereas others had a
wider scope of infective pathogens. Although the target
population for this review was patients with MRSA-
associated skin infections, the causative pathogen gener-
ally was unknown at trial entry; therefore, the inclusion
criteria for this review required a ‘suspicion’ of MRSA
rather than confirmed MRSA. Thus, where possible for
each outcome, a network including only MRSA popula-
tions was also assessed. However, conclusions for the
MRSA-only population should be drawn with care
because this encompassed an analysis group of limited
Fig. 5 Discontinuation due to adverse events: all trials. Odds ratios (fixed-effects model)
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size. Results for this network have been estimated using
only eight studies, whereas estimates for the all-trials
and ITT/mITT networks for the clinical response at
PTE were informed by 14 and 12 studies, respectively.
Because of the limited number of studies contributing
to each network, a pragmatic approach was adopted
whereby trials were included regardless of minor
differences in outcome definitions and analysis methods.
It was assumed that the differences in definitions and
methods would not influence the relative treatment
effects. These assumptions should be taken into consid-
eration when assessing the strength of the results.
Conclusions
Infections due to MRSA pose a considerable challenge
worldwide and are associated with increased mortality,
morbidity and healthcare costs. Therefore, identification
of optimal treatment strategies is of the utmost import-
ance, particularly in light of the declining efficacy of stand-
ard therapy. NMA is a useful analytical method that
allowed us to study the comparative efficacy and safety of
tedizolid and all established MRSA treatments even in the
absence of head-to-head trials for many of these agents.
This NMA showed that tedizolid may provide an alterna-
tive option for the management of serious skin infections
suspected or documented to be caused by MRSA.
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